

Esperer BioResearch launches health supplements for cancer patients

20 June 2019 | News

The initiative can benefit approximately 2.25 million people living with Cancer in India



Backed by a strong research on the nutritional deficiencies in cancer patients in India; Esperer BioResearch has launched 2 health supplements Es- Fortitude (nourish, protect & recovery) & Es- Invigour (base formula) in Delhi.

The supplements aim to bring optimal efficacy of the main therapy in cancer disease management to ensure better quality of life of patients across the globe.

One of the most relevant syndromes that increase as cancer progresses is cachexia that compromises the life of the patient and irremediably causes weakness and death. Hypermetabolism is correlated with clinical and biological markers of cancer cachexia and is associated with a shorter survival in metastatic cancer patients. Thus, there is a need for preparing the body for the treatment, during the treatment and during recovery stage. All 3 phases are different and require nutritional care basis the cell biology of the body.

Dr. Rakesh Chopra, Director Medical Oncology, Hematology & Bone Marrow Transplant Aakash Healthcare: Super Specialty Hospital - Dwarka; "Food is referred as metabolic therapy amongst Cancer patients. There are different changes in different metabolic pathways in different cells in different parts of the body. A scientific formula that can aid in maintaining the quality of life of the patient along with maintaining the nutritional balance is a promising progress. We look forward to prescribing such effective health supplements and revolutionary formulas for cancer care in the future."

Raktim Chattopadhyay, Founder & CEO said; "It is our endeavour to work towards a better quality of life for cancer patients. We believe that "Personalized Medicine" is our chance to revolutionize health care. Nutritional imbalance has a direct impact on the cancer disease and our quest is to mitigate the risk that stems from nutritional deficiency in cancer patients."

Manufactured at US-FDA approved nutraceutical plant at Bengaluru; the company has been researching and providing onco-nutrition therapy to cancer patients. Delhi recorded the maximum number of cancer incidences recent days.

The highest number of cancer cases recorded from Indian states were from Haryana at 39.6 % followed by Delhi at 27.3 % and Uttar Pradesh at 12.7%.

As per the data collated by Delhi's Cancer Registry shows that prostate cancer is the second most frequently diagnosed cancer among men in the city, just behind oral and lung cancer cases. The top cancers among men vary by area and include prostate, mouth, larynx, and esophagus. For women, breast cancer is consistently the highest incidence rate; this rate is also substantially higher in Delhi. Cervix Uteri and ovarian cancer are second and third respectively.